Showing results (161-170 of 243) with videos related to
Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP RegistryArianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.The Lancet. Oncology|May 19, 2022
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 studyMarjorie G Zauderer, Peter W Szlosarek, Sylvestre Le Moulec, et al.Cell Reports. Medicine|November 18, 2020
CD103<sup>+</sup>CD8<sup>+</sup> T<sub>RM</sub> Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17Stéphanie Corgnac, Ines Malenica, Laura Mezquita, et al.JCO Precision Oncology|September 11, 2020
Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung CancerJordi Remon, Ludovic Lacroix, Cecile Jovelet, et al.The New England Journal of Medicine|April 28, 2025
Zongertinib in Previously Treated <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Gerrina Ruiter, Myung-Ju Ahn, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System ProgressionMihaela Aldea, Lizza Hendriks, Laura Mezquita, et al.JTO Clinical and Research Reports|September 30, 2021
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief ReportDiego Enrico, Ludovic Lacroix, Jeanne Chen, et al.Lung Cancer (Amsterdam, Netherlands)|December 1, 2024
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohortAurélie Swalduz, Michèle Beau-Faller, David Planchard, et al.JAMA Network Open|November 12, 2025
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical TrialsPasi A Jänne, David Planchard, Koichi Goto, et al.Targeted Oncology|October 18, 2021
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and OutcomesChristos Chouaid, Thomas Filleron, Didier Debieuvre, et al.Pageof 25